Document is current
Any future updates will be listed below
-
Authors
Mahmoudjafari, Zahra https://orcid.org/0000-0002-3168-2521
Bhatt, Valkal
Galvin, John
Xue, Zhenyi
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Socié, Gérard https://orcid.org/0000-0002-2114-7533
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
- License Information
-
More Information
Article History
Received: 3 May 2024
Revised: 30 September 2024
Accepted: 11 October 2024
First Online: 6 November 2024
Competing interests
: ZM: Advisory board participation: AstraZeneca, BMS, Genentech, Janssen, KITE, Pfizer. RZ: Consulting fees and speaker bureau: Incyte, Medac, Mallinckrodt Pharmaceuticals/Therakos, Neovii, Novartis, Sanofi. FL: Consulting fees and speaker bureau: Amgen, Gilead, Miltenyi, Novartis, Sanofi, SOBI. GS: Consulting fees and speaker bureau: Allovir, Incyte, Novartis, Sanofi. MM: Declared no competing interests. VB, JG, and ZX are employees and shareholders of Incyte.
: Based on the retrospective post hoc analysis design of this study, no additional ethical approval or consent to participate was required. However, the REACH trials on which this study were based were designed and conducted in accordance with the International Council for Harmonisation Guideline for Good Clinical Practice, Declaration of Helsinki, and local regulatory requirements. Study protocols were approved by institutional review boards at each site. Patients or their guardians provided written informed consent for participation in the original REACH trials.
